Alan Mateo Biography and Net Worth

Director of 10x Genomics

Alan V. Mateo has served on our board of directors since June 2024. He currently serves as an advisor to Veeva Systems Inc., where he previously served as Executive Vice President, Global Sales from April 2015 to April 2024. Prior to joining Veeva, Mr. Mateo served in various executive roles at Medidata Solutions, Inc., a provider of a platform of cloud-based solutions for life sciences, from March 2005 to February 2015, including as Executive Vice President of Field Operations from January 2014 to February 2015. Before Medidata, Mr. Mateo spent nine years at PeopleSoft, where his responsibilities included product lines sales, sales operations and the integration of JD Edwards into PeopleSoft’s global sales organization. Prior to PeopleSoft, Mr. Mateo was Northeast Sales Director for Red Pepper Software Co., a provider of supply chain management planning application software, and a major account executive at JD Edwards. Mr. Mateo earned a Bachelor of Science in both Computer Science and Marketing from Juniata College.

What is Alan Mateo's net worth?: The estimated net worth of Alan Mateo is at least $543,806.17 as of February 21st, 2025. Mr. Mateo owns 61,691 shares of 10x Genomics stock worth more than $543,806 as of March 31st. This net worth estimate does not reflect any other assets that Mr. Mateo may own. Learn More about Alan Mateo's net worth.
How do I contact Alan Mateo?: The corporate mailing address for Mr. Mateo and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at investors@10xgenomics.com. Learn More on Alan Mateo's contact information.
Has Alan Mateo been buying or selling shares of 10x Genomics?: Within the last three months, Alan Mateo has bought $445,600.00 in 10x Genomics stock. Most recently, on Friday, February 21st, Alan Mateo bought 40,000 shares of 10x Genomics stock. The stock was acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. Learn More on Alan Mateo's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Alan Mateo (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, 10x Genomics insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $445,600.00. During the last year, insiders at the sold shares 8 times. They sold a total of 35,626 shares worth more than $712,955.88. The most recent insider tranaction occured on February, 24th when insider Benjamin J Hindson sold 4,573 shares worth more than $50,623.11. Insiders at 10x Genomics own 10.0% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 2/24/2025.

Alan Mateo Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/21/2025	Buy	40,000	$11.14	$445,600.00	61,691

Alan Mateo Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $8.73

$8.67

$8.99

50 Day Range

MA: $12.12

$9.16

$16.31

2 Week Range

Now: $8.73

$8.68

$37.86

Volume

2,397,540 shs

Average Volume

2,077,107 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93